RxDoctor Payments Data

Steven Busselen, MD

Family Medicine · Santa Barbara, CANPI 1689787202

Payments from drug & device makers

$3,724in general payments, 2019–2025

Across 179 payments — averaging $20.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$632
  • Gilead$471
  • Viiv Healthcare Company$448
  • AbbVie$406
  • Novo Nordisk$320
  • Pfizer$302
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$3,723100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,724 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$44,702
Medicare patients
400
Services billed
1,514

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin44$55,833
VivitrolNaltrexone Microspheres21$34,967
XareltoRivaroxaban18$17,984
ShingrixVaricella-Zoster Ge/As01b/Pf45$10,054
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl52$9,890
Incruse ElliptaUmeclidinium Bromide12$7,327
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$5,682
Boostrix TdapDiphth,pertuss(Acell),tet Vac31$2,185
Rosuvastatin Calcium102$1,562
Diclofenac Sodium14$1,432
Lidocaine11$1,339
Gabapentin52$1,088
KlonopinClonazepam12$1,012
Naltrexone Hcl11$847
Atorvastatin Calcium90$641

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$45$55,83344 claims
Alkermes, Inc.Vivitrol$32$34,96721 claims
GSKShingrix, Incruse Ellipta$200$17,38157 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →